Our results suggest that C3G may achieve therapeutic effects against RA and CIA by reducing the proportion of CD38+ NK cells to stimulate proportional changes in IL-10+ Treg cells and IL-10 secretion. Here, CD38 is linked to rheumatoid arthritis.